Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 148   

Articles published

BMY 50.58 -0.07 (-0.14%)
price chart
Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen ...
In Bristol-Myers Squibb Co (NYSE:BMY), Orbimed Advisors revealed holding 7.19 million shares, worth nearly $349 million. The stake represents an increase from 5.97 million shares the fund reported previously.
Related articles »  
Deutsche Bank Starts Bristol-Myers Squibb Co. (BMY) at Hold
Deutsche Bank initiated coverage on Bristol-Myers Squibb Co. (NYSE: BMY) with a Hold rating and a price target of $52.00. Analyst Gregg Gilbert said, "We are initiating coverage of Bristol Myers Squibb (BMY) with a Hold rating and $52 target price.
Bristol-Myers Squibb Receives Buy Rating from TheStreet (BMY)  WKRB News
Bristol-Myers Squibb Stock Rating Reaffirmed by TheStreet (BMY)  sleekmoney
Related articles »  
Analyst Update: Bristol-Myers Squibb Co, Eli Lilly and Co, and Merck & Co., Inc.
Analysts at Jefferies are weighing in today on big-cap drug stocks, including Bristol-Myers Squibb Co (NYSE:BMY), Eli Lilly and Co (NYSE:LLY), and Merck & Co.
Related articles »  
Fast Moving Stocks : Bristol-Myers Squibb Company (NYSE:BMY), InvenSense ...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer have announced data from a new clinical analysis showing the benefits of Eliquis in the treatment of venous thromboembolism (VTE).
Related articles »  
Bristol-Myers Squibb Becomes #111 Most Shorted S&P 500 Component ...
In our new rank based on the most recent short interest data from NASDAQ, Bristol-Myers Squibb Co. (NYSE: BMY) has taken over the position of #111 most shorted S&P 500 component, from Vulcan Materials Co (NYSE: VMC) which is now in the #220 spot.
Related articles »  
J&J And Bristol-Myers Changing The Myeloma Drug Landscape
Two players, Celgene Corporation (CELG) and Takeda Pharmaceutical Co Ltd (ADR) (TKPYY), have thus far dominated the myeloma market with their breakthrough drugs for years.
Bristol-Myers's Breakthrough Drug For HCV Gets Approved
Bristol-Myers Squibb Co. (BMY) announced yesterday that the European Commission (EC) has granted approval for the use of Daklinza, a drug developed for the treatment of the fatal Chronic Hepatitis C Virus (HCV) infection in adults.
European Commission Approves Bristol-Myers Squibb's Daklinza ...  MarketWatch
EU Approves Daklinza for the Treatment of Hepatitis C  HCPLive
Related articles »  
Traders Are Watching: Bristol-Myers Squibb Company (NYSE:BMY ...
On 20 AUG Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq: CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of ...
Allied Minds, Bristol-Myers Squibb Form New Company - Quick Facts
Allied Minds PLC (ALM.L) and Bristol-Myers Squibb Co.(BMY: Quote) has agreed to form a jointly owned new company called Allied-Bristol Life Sciences LLC, for translating early-stage academic innovation to therapeutic candidates for clinical study.
Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance ...  Wall Street Journal
Bristol-Myers Squibb form company with Allied Minds for research and ...  The Pharma Letter
Related articles »  
3 Reasons Bristol-Myers Squibb's Stock Could Rise
Despite slumping sales for key drugs, Bristol-Myers had generated strong top-line growth through its lucrative diabetes collaboration with AstraZeneca (NYSE: AZN ) , which culminated in the co-purchase of Amylin Pharmaceuticals in 2012. Nevertheless ...
Related articles »